PDCD1 and neoplasm: This precisely targeted feature could help cytokine therapy and programmed cell death protein 1 (PD-1)/programmed cell death 1 ligand 1 (PD-L1) antibody in ICB therapy solve the problem of systemic toxicity and help tumor vaccines solve the problem of complex transport in vivo.